So a big campaign of ours is getting that across to the physicians to say, look, you’re just temporizing these patients, you’re giving them a temporary solution for a chronic problem, let’s get them back in here, let’s talk to them about a long-term multi-decade solution that will solve their problems. So we don’t need to find, the patients are already there, and this is a point that I think is maybe counterintuitive, it’s just counterintuitive, we think that, well, you go see a urologist, they’re going to spend time or urogynecologist, they’re going to spend time with you, they’re going to talk to you about all the treatment options, but the reality is if you take a stop watching and you went in and installed what actually happened, I mean they’re spending minutes, only minutes with these patients, and so that’s part of the issue.
So you can see why we’re doing all these other things. Why do we have storybooks? Why do we have clinical specialists, why are we providing DTC, we’re trying to help patients identify themselves and wave their hands in front of the office and say, hey, I’ve got this problem, help me, don’t give me another drug prescription that doesn’t work. So, I think there’s nothing really new about this, it’s just – this is what’s going on and I mean there are 10s of millions of people that are just sitting out there right now and they’re not getting the treatment that they deserve and we’re going to do our little part to see that more of these patients get treated and I mean if the DTC numbers don’t really get the point across, I don’t know what else would.
I mean 11,000 and 12,000 people are filling out our symptom questionnaire and saying, please connect me with a local provider in my community to get evaluated, these are incredible numbers. And once again pale in comparison to the number of patients that are already sitting in EMR systems or file cabinets of customer locations around the United States. So we really appreciate that question, you’ve helped us even further inform about this topic.
Shagun Singh: Thank you.
Operator: Thank you. Our next question comes from the line of Michael Sarcone with Jefferies. Your line is now open.
Michael Sarcone: Thanks. Hi, Ray, Dan, and Neil. Thanks for squeezing me in here. That’s just one follow-up on the DTC campaign. It does look like you’re gaining some steam there. You talked about over 11,000 qualified leads in January, could you just give us an update on kind of what the mix of those patients looks like, I know in the past you’ve talked about 60% treatment-naive, so any update there? And then, when do you think you might start being able to mine some of the patients in terms of implants that come in through the funnel?
Raymond Cohen: So, Michael, thanks for the question. It’s already happening. We are able to now start to make a direct correlation between patient names that have filled out questionnaires and those who are getting treated. The numbers are growing. We’re seeing – we’ve said it’s about a six-month gestation period before we could truly expect stuff. We are starting to see it, it is measurable. We’re very encouraged by that. Having said that, nothing has changed, I mean, it may be even more patients who – or more people who are filling out these questionnaires that are treatment-naive. So I think once again that just underscores how generally speaking the population here in the United States is unaware that there are advanced therapies to treat this problem.
